Surrozen vs Voyager Therapeutics
SRZN and VYGR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SRZN and VYGR compare
Surrozen is the larger company, worth 3.5 times as much as Voyager Therapeutics ($372M against $107M).
Surrozen grew revenue faster over the last twelve months (−8.8% versus −19.8% for Voyager Therapeutics).
Voyager Therapeutics keeps more of each dollar of sales as profit, with a net margin of −416% compared with −2885% at Surrozen.
Voyager Therapeutics scores higher on the StockData Score (8 against 5 for Surrozen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SRZN | VYGR |
|---|---|---|
| Size and price | ||
| Market cap | $372M | $107M |
| Share price | $31.61 | $1.73 |
| Change, 1 year | 144% | −59.3% |
| Change, 5 years | −77.1% | −47.4% |
| Beta (5Y) | 0.52 | 1.19 |
| Employees | 44 | 141 |
| StockData Score | ||
| Total score | 5 | 8 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 32.3× | 4.2× (better) |
| P/B | – | 0.8× |
| FCF yield | −9.4% (better) | −103% |
| Fair value | – | $2.87 |
| Margin of safety | – | 39.7% |
| Growth | ||
| Revenue growth (TTM) | −8.8% (better) | −19.8% |
| Revenue growth, 5Y average | – | −25.1% |
| Profitability | ||
| Operating margin | −385% (better) | −450% |
| Net margin | −2885% | −416% (better) |
| FCF margin | −304% (better) | −437% |
| Return on equity | – | −58.9% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 12.14 (better) | 6.81 |
| Altman Z-score | −6.78 | −3.91 (better) |
| Piotroski F-score | 3 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −0.94% | – |
| Shareholder yield | −0.94% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 91.3% | 56.9% |
| Held by insiders | 44.5% | 2.6% |
| Insider net buying, 12 months | $1.6M (better) | −$298K |
| Short interest, % of float | 49.6% | 7.3% |
Go deeper
- SRZN stock overview
- SRZN income statement
- SRZN valuation and score
- VYGR stock overview
- VYGR income statement
- VYGR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.